Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Drug-Induced Dyskinesia. According to GlobalData, Phase II drugs for Drug-Induced Dyskinesia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Safinamide mesylate LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Safinamide mesylate overview
Safinamide mesylate (Xadago,Equfina ) is an alpha-aminoamide derivative act as add-on therapy to dopamine agonists or levodopa. It is formulated as film-coated tablets for oral route of administration. Xadago is indicated in the treatment of idiopathic Parkinson's disease (PD) or for mid-to late-stage fluctuating patients as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products.
It is under development for the treatment of multiple system atrophy (MSA), levodopa-induced dyskinesia and Parkinson's disease in Israel and Mexico. It was also under development for the treatment of restless legs syndrome and amyotrophic lateral sclerosis.
Zambon Co overview
Zambon Co (Zambon) manufactures pharmaceutical and fine chemical products. The company offers pharmaceutical products for the respiratory, central nervous system, pain management, women’s healthcare, and rare diseases and specialties, including Parkinson’s disease and cystic fibrosis. It also provides active pharmaceutical ingredients (API), intermediates and custom synthesis services. The company has manufacturing plants in Cadempino, Switzerland; Haikou, China; Vicenza, Italy; and Barueri, Brazil. It distributes products directly and also through a network of distributors across North America, Latin America, Europe, the Middle East, and Africa, and Asia. Zambon is headquartered in Milano, Italy.
For a complete picture of Safinamide mesylate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
